Patents by Inventor Georg Jaeschke
Georg Jaeschke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11708354Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: GrantFiled: November 24, 2020Date of Patent: July 25, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Patent number: 11673902Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.Type: GrantFiled: June 17, 2022Date of Patent: June 13, 2023Assignee: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
-
Publication number: 20230110648Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.Type: ApplicationFiled: June 17, 2022Publication date: April 13, 2023Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
-
Publication number: 20230057891Abstract: The application provides a compound having the general formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: December 18, 2020Publication date: February 23, 2023Applicant: Hoffmann-La Roche Inc.Inventors: David Stephen HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI
-
Publication number: 20230054473Abstract: The application relates to (106) specific heterocyclic compounds comprising a thiazole ring, an indazol and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole system, to pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: February 23, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20230034696Abstract: The application provides a compound having the general formula (I) or a pharmaceutically acceptable salt thereof, compositions including the compound and methods of using the compound. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: December 18, 2020Publication date: February 2, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI
-
Publication number: 20220315593Abstract: The application relates to 6 specific heterocyclic compounds, pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315591Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Roger David NORCROSS, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315577Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R3, R4, R5 and R10 are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315592Abstract: The application relates to a compound of formula (I) containing a thiazole ring, an indazol ring and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole ring system, to pharmaceutical compositions containing it and its medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220169599Abstract: The present invention provides new arylsulfonamide compounds having the general formula (I) wherein L, R1, R2, R3 and R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: February 15, 2022Publication date: June 2, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Barbara BIEMANS, Luca GOBBI, Georg JAESCHKE, Henner KNUST, Lothar LINDEMANN, Fionn O'HARA, Jean-Marc PLANCHER
-
Patent number: 11345708Abstract: The present invention relates to compounds of formula I wherein L is a bond, a triple bond, —C(O)NH— or —NHC(O)—; R1 is phenyl or a five or six-membered heteroaryl group, optionally substituted by lower alkyl, lower alkyl substituted by halogen or lower alkoxy substituted by halogen; R2 is fluoro; R3 is fluoro or chloro; R4 is hydrogen, lower alkyl, halogen, lower alkyl substituted by hydroxy, S(O)2CH3, or is a five or six-membered heteroaryl group or a heterocycloalkyl group, which are optionally substituted by lower alkyl, hydroxy or ?O; R5 and R6 are both methyl and the dotted line is a bond, or R5 and R6 are both methyl and the dotted line is nothing, or one of R5 and R6 is hydrogen and the other is methyl, and the dotted line is nothing; or to a pharmaceutically acceptable salt or acid addition salt, to all possible tautomeric forms, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.Type: GrantFiled: February 13, 2020Date of Patent: May 31, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Georg Jaeschke, Fionn O'Hara, Eric Vieira
-
Publication number: 20220135571Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: December 21, 2021Publication date: May 5, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, Annick Goergler, Georg Jaeschke, Bernd Kuhn, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner, David Hewings, Yvonne Alice Nagel
-
Publication number: 20220127275Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.Type: ApplicationFiled: January 4, 2022Publication date: April 28, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Barbara BIEMANS, Georg JAESCHKE, Antonio RICCI, Daniel RUEHER, Fionn O'HARA
-
Publication number: 20220112199Abstract: The invention provides novel a compound having the general formula (I) as described herein, compositions including the compound and methods of using the compound.Type: ApplicationFiled: December 21, 2021Publication date: April 14, 2022Inventors: Cosimo Dolente, Annick Goergler, David Hewings, Georg Jaeschke, Bernd Kuhn, Yvonne Alice Nagel, Roger David Norcross, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Patent number: 11242349Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.Type: GrantFiled: May 1, 2020Date of Patent: February 8, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Barbara Biemans, Georg Jaeschke, Antonio Ricci, Daniel Rueher, Fionn O'Hara
-
Publication number: 20210300844Abstract: The present invention relates to ethynyl derivatives of formula I with variables as defined herein, or to a pharmaceutically acceptable acid addition salt thereof Compounds of formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).Type: ApplicationFiled: June 3, 2021Publication date: September 30, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Georg Jaeschke, Lothar Lindemann, Antonio Ricci, Eric Vieira
-
Patent number: 11117890Abstract: The present invention provides substituted isoindole compounds which are selective allosteric EGFR inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, generally of Formula: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 2, 2019Date of Patent: September 14, 2021Assignee: Hoffman La-Roche Inc.Inventors: Georg Jaeschke, Antonio Ricci, Daniel Rueher, Sandra Steiner, Martin Duplessis, Yvonne Alice Nagel, Bernd Kuhn
-
Publication number: 20210269452Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.Type: ApplicationFiled: May 9, 2021Publication date: September 2, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
-
Patent number: 11059766Abstract: The present invention relates to ethynyl derivatives of formula I with variables as defined herein, or to a pharmaceutically acceptable acid addition salt thereof. Compounds of formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).Type: GrantFiled: December 1, 2017Date of Patent: July 13, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Georg Jaeschke, Lothar Lindemann, Antonio Ricci, Eric Vieira